AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01617356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection of 20% dextrose/ 0.2% lidocaine
Description: Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
Study NCT02579109 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: memory test
Study NCT00799331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5985
Description: Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.
Study NCT00799331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral suspension.
Study NCT02789488 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fenugreek seeds extract 500 mg
Description: Furocyst one caps BID
Study NCT02135315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate
Description: administration of continuous intravenous isosorbide dinitrate to obtain a SBP between 110 and 120 mmHg. After 2 hours from the start of treatment and if the blood pressure goal is not achieved, labetalol is used
Study NCT02135315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: administration of continuous intravenous isosorbide dinitrate to obtain a SBP between 110 and 120 mmHg. After 2 hours from the start of treatment and if the blood pressure goal is not achieved, labetalol is used
Study NCT05967845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cartilage tympanoplasty
Description: cartilage tympanoplasty procedure entails repairing the tympanic membrane perforation by using a piece of cartilage harvested from the patient's auricle.
Study NCT05967845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich fibrin augmented tympanoplasty
Description: platelet rich fibrin augmented tympanoplasty entails performing the traditional tympanoplasty using the tempralis fascia as a grafting material. However, platelet rich fibrin clot is obtained from the patient's own blood, and applied to the graft to enhance healing process.
Study NCT03220815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drilling at low speed
Study NCT02207712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Standard ranibizumab treatment only
Study NCT04539912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: angulated screw retained crown
Description: ASC abutment was used in AG;
Study NCT04539912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cemented crown
Description: prefabricated Ti abutment was used in CG
Study NCT02501018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLBS12
Description: Intramuscular transfusion of CLBS12.
Study NCT02501018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).
Study NCT02501018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).
Study NCT02304666 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonoscopy for biopsies samples
Study NCT02304666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy for biopsies samples
Study NCT01263938 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: For subjects on PI-based HAART therapy: 10mg/day X 2weeks followed by 20mg/day.~For subjects on non PI-based HAART therapy: 20mg/day X 2weeks followed by 40mg/day.
Study NCT03097991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused Coparenting Consultation
Description: Six 90-minute sessions completed within 10 weeks address importance of coparenting for child development; overcoming challenges to coparenting collaboratively; anger and conflict management and communication skills. Parents develop a coparenting plan to support one another's involvement as parents to the baby. A 90-minute booster session one month after the baby's birth reinforces lessons learned in the 6-session intervention.
Study NCT03220815 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional drilling at high speed
Study NCT02418104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-1701
Study NCT02418104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim (Neulasta)
Study NCT01779245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Milk-extracted calcium supplement will be used to modulate the calcium content of the milkshakes used.
Study NCT01779245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03150589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB11 (Proposed ranibizumab biosimilar)
Description: SB11 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
Study NCT03150589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis (ranibizumab)
Description: Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
Study NCT03597152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: WelTract
Description: Supplement commercially available from the sponsor containing powdered extracts from Hibiscus flowers and cranberry fruit, lactoferrin, D-mannose, and vitamins C and D
Study NCT03597152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert placebo custom manufactured for the sponsor
Study NCT01214109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole extended release
Description: 0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
Study NCT01214109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole extended release
Description: 0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
Study NCT01214109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole immediate release
Description: 0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
Study NCT01214109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole immediate release
Description: 0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
Study NCT02451072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules containing mannitol looking identical to LSD per os
Study NCT02451072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSD
Description: 100µg per os, single dose
Study NCT02451072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketanserin
Description: 40mg per os, single dose looking identical to LSD per os
Study NCT04943640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio taping
Description: Kinesio tape was developed by Kenzo Kase in the 1970s. It is an elastic tape, and its adhesive face is sinusoidal wavy. This feature has been shown to increase daily living activities and functions, as it supports the tissue while also allowing movement \[12\]. Kinesio tape lifts the skin and subcutaneous soft tissues of the fascia, which are painful and inflamed regions upon contractions seen in the tissue after tense adhesion to the skin. Therefore, it has been reported to reduce oedema and inflammation by creating more space and providing blood and lymphatic fluid flow.
Study NCT04943640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rigid taping
Description: The tape material used in rigid (athletic) tape application is hard. It is used to position and unite the soft tissue, to protect the tissue from impact and to prevent local swelling.There are studies in the literature supporting the sensorimotor and proprioceptive sensation-enhancing effect of the athletic band, which provides a very good sensory input through the skin.
Study NCT04943640 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo taping
Description: Placebo taping was applied to the patients in this group, using betafix, an elastic fixation band, as the material. The patient was told that taping would be applied. A straight line betafix was applied to the non-painful scapular inferior level of the spine on the right and left sides of the standing patient.
Study NCT03973021 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Very small embryonic-like stem cell(VSEL)
Description: Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
Study NCT01502839 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This retrospective data analysis will rely on data obtained from chart review.
Study NCT02471872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Air Pollution Education
Description: Students are presented with a one-hour interactive session on air pollution.
Study NCT02471872 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Air Pollution Education
Description: Students are presented with a one-hour interactive session on vaccines.
Study NCT01571947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute Effects of Fats and Carbohydrate
Description: Test meals were served in the form of muffin + milkshake. For high fat meals, 55g of test fat will be incorporated in muffins, whereas 22g of fat for low fat or high carbohydrate test meal. During study day, subjects were to consume the allocated test meal within 10 minutes.
Study NCT00490906 — intervention group
Intervention type: DRUG
Intervention: Copaxone
Description: 20 mg, subcutaneous injections, taken daily
Study NCT00490906 — intervention group
Intervention type: DRUG
Intervention: Interferon-beta 1a
Description: 30 mcg injected intramuscularly, once weekly
Study NCT00490906 — intervention group
Intervention type: DRUG
Intervention: Interferon-beta 1b
Description: .25 mg/day, taken every other day, subcutaneous injections
Study NCT01617356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection of 1 ml of 0.8 SW/0.2% lidocaine
Description: Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine.
Study NCT03525964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized treatment of Acute Achilles tendon rupture.
Description: The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the Achilles tendon and the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon and consist of the free tendon and the fascia \[1\]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively. The cut-off at 7% elongation is determined for 75% sensitivity and 65% specificity of elongation.
Study NCT03525964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative treatment
Description: Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
Study NCT03525964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative treatment
Description: Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
Study NCT03467360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetazolamide in combination with platinum and etoposide-based radiochemotherapy
Description: Radiation therapy will be combined with platinum and etoposide-based chemotherapy combined with 3-6 tablets per day of acetazolamide during the entire course of therapy (dosage appropriate to the inclusion phase).
Study NCT03467360 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC
Description: acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC
Study NCT00370513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.
Study NCT00861718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7268
Description: Capsule, Oral, QD
Study NCT00861718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7268
Description: Capsule, Oral, BID
Study NCT00861718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral BID
Study NCT04093804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glenosphere size for Reverse Shoulder Arthroplasty
Description: Two randomized study groups will be formed with the consented patients (experimental and control). All patients will undergo reverse shoulder arthroplasty by the Principal Investigator. The experimental group patients will receive a 36mm glenosphere and the control group will receive a 32mm glenosphere. All other procedures during the surgery are identical between groups.
Study NCT04093804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glenosphere size for Reverse Shoulder Arthroplasty
Description: Two randomized study groups will be formed with the consented patients (experimental and control). All patients will undergo reverse shoulder arthroplasty by the Principal Investigator. The experimental group patients will receive a 36mm glenosphere and the control group will receive a 32mm glenosphere. All other procedures during the surgery are identical between groups.
Study NCT02472613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Patients will be treated at Renzhong（Du26）, Yintang（EX-HN3）、accupuncture Shangxing（DU23）penetrate to Baihui（DU20）,Sishencong（EX-HN1）; Neiguan（PC6）,Sibai（ST2）,Fengchi（GB20）and Sanyinjiao（SP6）in bilateral;Jianyu（LI15）,Quchi（LI11）,Shousanli（LI10）,Hegu（LI 4）, Fengshi (GB31),Xuehai（SP10） ,Zusanli（ST36）、Taichong（LR 3） of the hemiplegia side. There are another six groups of acupoints in bilateral. The acupuncturist will choose one group acupoints according to patients syndrome:Zhigou (SJ6),Qimen (LR14);Xingjian (LR2),Xiaxi(GB43);Fenglong (ST40),Lianquan(RN23);Tongli (HT5),Xinshu (BL15);Xinshu (BL15),Pishu(BL20);Shenshu (BL23),Taixi (KI3).~The acupoints are inserted at the depth of 20-30mm except Renzhong（Du26）, Sibai（ST2）, Sishencong（EX-HN1）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks.
Study NCT02472613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo was given for 12 consecutive weeks.
Study NCT02472613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham-acupoint acupuncture
Description: Jianliao（SJ14）,Tianquan（PC2）,Xiabai (LU4),Xiaoluo (SJ12),Shouwuli (LI13),Sidu (SJ9),Huizong (SJ7),Wenliu (LI7),Zhouliao (LI12),Quze（PC3）,Kongzui（LI6）,Zhigou（SJ6）,Zhongzhu（SJ3）,Futu（ST32）,Jimen (SP11),Yinshi (ST33),Liangqiu（ST34）,Shangjuxu（ST37）,Xiajuxu（ST39）,Xiyangguan（GB33）,Ligou（LR5）,Pucan (BL61),Jinggu (BL64),Rangu (KI2),Ligou (LR5),Neiting （ST44） of the hemiplegia side.~• The acupoints are inserted at the depth of 20-30mm,except Pucan (BL61),Jinggu (BL64),Rangu (KI2) ,Neiting （ST44）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks.
Study NCT02472613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine was given at a dose of 20 mg/day for12 consecutive weeks.
Study NCT01030614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: intravenous dexamethasone 8 mgr before laparoscopic cholecystectomy or intravenous placebo before laparoscopic cholecystectomy
Study NCT01030614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: intravenous dexamethasone 8 mgr before laparoscopic cholecystectomy or intravenous placebo before laparoscopic cholecystectomy
Study NCT01030614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
Study NCT03046979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
Study NCT03307031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Volume Group
Description: Performed four weekly session, during 10 weeks with 45 to 55 minutes per session.
Study NCT03307031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Volume Group
Description: Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
Study NCT03307031 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Did not exercise, during 10 weeks.
Study NCT04748159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone position/ Abdominal position
Description: Standardized positioning of the infant in the prone position respectively abdominal position. Depending on age and size, one or two rolled towels are placed lengthwise under the baby. Both arms are placed cranially in U-position towards the head. Since the position of the head has no significant influence on lung ventilation, the head is placed according to the infant's tolerance.
Study NCT02567591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: walk (three times per week) and muscle building twice per week with the use of elastic bands. They will include 5 strengthening exercises mobilizing large muscle groups of the lower limbs (abs (if possible for the patient), hamstrings, quadriceps, triceps sural and gluteus maximus).
Study NCT05560386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: text messaging content to support diabetes prevention.
Study NCT05560386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual workshop
Description: virtual workshop content to support diabetes prevention.
Study NCT02095444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menstrual blood stem cells
Description: 10\*7 cells/kg, intravenous injection for 4 times during two weeks
Study NCT00847964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algisyl-LVR
Description: method of left ventricular restoration in patients with dilated cardiomyopathy
Study NCT01362543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural therapy (stress management)
Description: Following a manual
Study NCT01362543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy (cognitive restructuring)
Description: Following a manual
Study NCT02158715 — intervention group
Intervention type: DEVICE
Intervention: Site of smartphone on chest compressor' arm
Study NCT01597934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A (Zeffix, Sebivo, Hepsera)
Description: Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
Study NCT01597934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B (Baraclude, Viread)
Description: Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
Study NCT02699489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy
Description: Laparoscopic donor nephrectomy performed via a standard 4-port distribution. Control of the hilar vessels is performed using extra-large Hem-o-Lok clips (Weck- Covidien, Research Triangle Park, NC) and graft extraction is performed via a pre-prepared Pfannenstiel incision
Study NCT02699489 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open donor nephrectomy
Description: Open donor nephrectomy performed via a supracostal incision above the 11th rib and an extra-pleural extra-peritoneal approach was adopted
Study NCT01314261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: 5 mg or 25 mg tablets
Study NCT01105585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecnis 1-piece Aspheric Acrylic (ZCB00) IOL
Description: Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
Study NCT01105585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AcrySof Natural IQ (SN60WF) IOL
Description: AcrySof Natural IQ (SN60WF) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
Study NCT00915148 — intervention group
Intervention type: OTHER
Intervention: Ultrasound examination
Description: Trans-abdominal and trans-perineal 3D ultrasound examination